Résumé
Background: We did a randomised, double-blind, controlled clinical trial to prospectively assess whether use of combination antibiotic susceptibility testing improved clinical outcomes in patients with acute pulmonary exacerbations of cystic fibrosis who were infected with multiresistant bacteria. Methods: 251 patients with cystic fibrosis who were chronically infected with multiresistant gram negative bacteria gave sputum at 3-month intervals for conventional culture and sensitivity tests and for combination antibiotic susceptibility tests using multiple combination bactericidal antibiotic testing (MCBT). Patients who developed an exacerbation of pulmonary disease were randomised to receive a 14-day course of any two blinded intravenous antibiotics chosen on the basis of either results from conventional sputum culture and sensitivity testing or the result of MCBT. The primary outcome was time from randomisation until the patient's next pulmonary exacerbation. Analysis was by intention-to-treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN60187870. Findings: 132 patients had a pulmonary exacerbation and were randomised during the 4.5-year study period. The time to next pulmonary exacerbation was not prolonged in the MCBT-treated group (hazard ratio 0.86 in favour of the conventionally-treated group, 95% CI 0.60-1.23, p=0.40). There was no difference between the groups in treatment failure rate. After 14 days of intravenous antibiotic therapy, changes in lung function, dyspnoea, and sputum bacterial density were similar in both groups. Interpretation: Antibiotic therapy directed by combination antibiotic susceptibility testing did not result in better clinical and bacteriological outcomes compared with therapy directed by standard culture and sensitivity techniques. The non-bactericidal effects of antibiotic therapy might play an important part in determining improvement in patients with cystic fibrosis pulmonary exacerbations.
| Langue d'origine | English |
|---|---|
| Pages (de-à) | 463-471 |
| Nombre de pages | 9 |
| Journal | The Lancet |
| Volume | 366 |
| Numéro de publication | 9484 |
| DOI | |
| Statut de publication | Published - août 6 2005 |
Note bibliographique
Funding Information:We are indebted to the following for their assistance: study coordinators, Pat Hazell, Francis Gosse, Kathleen Devecseri, Lesley Gaskin, Holly Truchan, Vanja Dijak, Patrice Kean, Carol Verwolf, Jennifer Jackson Lee, Josette Salgado, Joan Tabak, Manon Roussin, Nadia Beaudoin, Rosamund Hennessey, Carmel Moriarty, and Elizabeth Sheppard; study microbiologists, Randall Wilson and Melissa St Denis; coordinating study pharmacist, Anne Marie Dugal; study site pharmacists, Debi Snow, Susan Fetzer, Laura Parsons, Shawn Launder, Mara Pavan, Ron Wall, Leba Barrow, Janet Knechtel, Rita Pon, Jeff Lau, Luc Bergeron, Monique Thibault, Gita Sobhi, Gerry Peckham, Judith Burrows, and Dora Agaliotis; physicians who assisted, Robert Dales, Douglas McKim, Roger Michael, Nancy Morrison and Linda Pedder; statistical consultant Jennifer Clinch; and Chiron Corporation for supplying TOBI (inhaled tobramycin) and placebo tobramycin to the Canadian study sites. This study was funded by grants from The Canadian Institutes of Health Research (C$319 225), The Australian CF Trust (A$138 000), Astra-Zeneca Canada Inc (unrestricted research grant, C$150 000), and The Canadian CF Foundation (C$98 526). Dr Aaron is supported by a Canadian Institute of Health Research New Investigator Award.
ASJC Scopus Subject Areas
- General Medicine